[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Israelita Albert Einstein\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":680},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,46,75,108,136,172,194,221,245,274,300,329,359,380,398,423,449,471,499,527,562,584,613,638,659],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639880","study-on-the-functional-impact-of-cosmetics-on-improving-self-esteem-and-quality-of-life-in-black-women-100639880",false,"NCT07618572","Study on the Functional Impact of Cosmetics on Improving Self-Esteem and Quality of Life in Black Women","Inclusion Criteria:\n\n* Female participants aged 18 to 55 years\n* Clinical diagnosis of facial post-inflammatory hyperpigmentation (PIH)\n* Self-identified as Black (including \"preta\" or \"parda\")\n* Fitzpatrick skin types IV to VI\n* Employees, students, or affiliated personnel of Hospital Israelita Albert Einstein (including contractors and fellows), recruited from institution units\n* Willing and able to comply with all study procedures and attend all scheduled visits\n* Able and willing to provide written informed consent and authorization for image use\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or those planning pregnancy during the study period\n* Type 1 diabetes mellitus or related complications (e.g., nephropathy, dermatological conditions associated with diabetes, history of hypoglycemia, diabetic ketoacidosis, or hyperosmolar coma)\n* Known or suspected intolerance to similar cosmetic products\n* History of atopy or allergic reactions to cosmetic products\n* Personal or family history of skin cancer\n* Active skin conditions or lesions affecting the face\n* Facial marks or scars that may interfere with assessments\n* Skin irritation due to recent sun exposure\n* Excessive sun or UV exposure, including artificial tanning, within the past month\n* Use of facial cosmetic products within 7 days before screening\n* Use of topical or systemic treatments within 1 month before screening\n* Use of depigmentation treatments within 3 months before screening\n* Use of dermocosmetic treatments for PIH within 3 months before screening\n* Facial dermatological or aesthetic procedures within 2 weeks before screening\n* Use of corticosteroids, anticoagulants, or immunosuppressive drugs\n* Score ≥5 indicating anxiety or depression on Patient Health Questionnaire (PHQ-9) or Generalized Anxiety Disorder scale (GAD-7)\n* Any other condition that, in the investigator's judgment, may compromise study participation or results (to be documented in the medical record)","FEMALE","18 Years","55 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate whether the use of dermocosmetics containing Bioceramides and Niacinamide can improve post-inflammatory hyperpigmentation and promote positive impacts on self-esteem and quality of life in Brazilian Black women with facial hyperpigmentation (Fitzpatrick skin types IV to VI).\n\nThe main questions it aims to answer are:\n\n* Does the treatment improve hyperpigmentation severity as measured by HASI and IGA scores?\n* Does the treatment improve participants' self-esteem and quality of life as assessed by MELASQoL and DLQI questionnaires?\n\nParticipants will:\n\n* Use a standardized skincare routine including cleanser (0.2% Bioceramides), moisturizer (2% Niacinamide + 1% Bioceramides), serum (5% Niacinamide + 3% Bioceramides), and SPF 30 sunscreen for 12 weeks.\n* Attend study visits at baseline, week 6, and week 12.\n* Undergo standardized facial photography and clinical assessments by specialists at baseline, week 6, and week 12.\n* Complete questionnaires related to self-esteem and quality of life at baseline, week 6, and week 12.",[27],"Post-inflammatory Hyperpigmentation",[27,29,30,31,32],"Bioceramides","Niacinamide","Black Women","Facial Hyperpigmentation","RECRUITING","2026-06-02",{"date":36,"type":37},"2026-06-04","ACTUAL",{"date":39,"type":37},"2026-03-19",{"date":41,"type":21},"2026-10-31",{"name":43,"class":44},"Hospital Israelita Albert Einstein","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100639972","intensive-care-unit-conflict-mediation-study-100639972","NCT07621874","Intensive Care Unit Conflict Mediation Study","A Multidisciplinary Framework for ICU Conflict Mediation: Rationale and Methodological Approach to Enhancing Safety and Care Quality","\"GIRAFFE\"","-family members of patients or intensive care unit staff",true,"ALL",{"count":57,"type":21},100,[24],"To evaluate the impact of a structured, multidisciplinary conflict management program incorporating an interprofessional Singular Care Plan \\*PAS\\* Committee and a Conflict Mediation Team on the incidence and severity of conflicts, family satisfaction, and staff well-being in an adult intensive care unit \\*ICU\\*",[61,62,63],"Aggression","Critical Care Staff","Workplace Violence",[61,65,66],"critical care","Workplace violence","NOT_YET_RECRUITING","2026-06-01",{"date":34,"type":37},{"date":71,"type":21},"2026-10-01",{"date":73,"type":21},"2027-08-01",{"name":43,"class":44},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100595055","acute-treatment-and-long-term-assessment-of-adult-infectious-meningitis-100595055","NCT07027475","Acute Treatment and Long-term Assessment of Adult Infectious Meningitis","Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Adults Meningitis","ATLAS-I","Inclusion Criteria:\n\n* Fever (axillary temperature ≥37.8°C) followed by two or more of the following symptoms: severe headache, vomiting, altered consciousness (confusion, drowsiness, or irritability), photophobia (increased sensitivity to light), presence of seizures OR\n* Fever accompanied by at least one meningeal irritation sign, such as neck stiffness, Kernig's sign, or Brudzinski's sign OR\n* Sudden onset of fever and appearance of petechial skin rash or hemorrhagic suffusions\n\nExclusion Criteria:\n\n\\- Refusal to provide consent for study participation",{"count":84,"type":21},624,"6 Months","OBSERVATIONAL","Prospective, multicenter, observational clinical registry of adult patients with acute infectious meningitis across approximately 30 public and private hospitals in Brazil. The study will include adults, 18 years old and older, with suspected acute infectious meningitis. Data will be collected during hospitalization and post-discharge to evaluate clinical management, treatment and short and long-term outcomes. The study aims to generate real-world evidence on current practices and outcomes to support improvements in national care protocols.",[89,90,91,92],"Viral Meningitis","Bacterial Meningitis","Fungal Meningitis","Meningitis",[92,94,95,96,97,98],"Bacterial","Viral","Corticosteroids","Antibiotics","Fungal","2026-05-04",{"date":101,"type":37},"2026-05-07",{"date":103,"type":37},"2026-03-30",{"date":105,"type":21},"2027-02",{"name":43,"class":44},3,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":55,"minAge":4,"maxAge":115,"enrollmentInfo":116,"targetDuration":118,"studyType":86,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":45},"100597742","prospective-clinical-registry-of-acute-treatment-and-long-term-assessment-of-children-meningitis-100597742","NCT07062445","Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Children Meningitis","ATLAS-II","Inclusion Criteria:\n\n* Fever (axillary temperature ≥37.8°C) followed by two or more of the following symptoms\\*: severe headache, vomiting, altered consciousness (confusion, drowsiness, or irritability), photophobia (increased sensitivity to light), presence of seizures OR\n* Fever accompanied by at least one meningeal irritation sign, such as neck stiffness, Kernig's sign, or Brudzinski's sign OR\n* Sudden onset of fever and appearance of petechial skin rash or hemorrhagic suffusions\n\n  * In children younger than two years, in addition to the presentations listed above, consider fever with any of the following: irritability, persistent crying, somnolence, or bulging fontanelle.\n\nExclusion Criteria:\n\n* Refusal to provide consent for study participation","17 Years",{"count":117,"type":21},600,"180 Days","Prospective, multicenter, observational clinical registry of pediatric patients with acute infectious meningitis across approximately 20 public and private hospitals in Brazil. The study will include children under 18 years of age with suspected acute infectious meningitis. Data will be collected during hospitalization and post-discharge to evaluate clinical management, treatment and short and long-term outcomes. The study aims to generate real-world evidence on current practices and outcomes to support improvements in national care protocols.",[92,121,89,91],"Bacterial Infections",[123,124,125,126,127,128],"meningitis","bacterial","virus","corticosteroids","antibiotics","fungal","2026-04-29",{"date":131,"type":37},"2026-05-05",{"date":133,"type":37},"2026-03-29",{"date":105,"type":21},{"name":43,"class":44},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":154,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},"100610919","hydrogen-peroxide-and-ultraviolet-light-for-disinfecting-surfaces-in-intensive-care-units-100610919","NCT07233837","Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units","Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units: A Randomized, Controlled, Cluster, Crossover Clinical Trial","Hylight","Inclusion Criteria:\n\n* All patients aged 18 years and older who will be admitted to the participating ICUs\n\nExclusion Criteria:\n\n* Patients under 18 years\n* ICUs that use peroxide hydrogen or ultraviolet light for surface disinfection as part of their protocol",{"count":145,"type":21},5000,[24],"Healthcare-associated infections (HAIs) remain a major problem in intensive care units (ICUs), driven by environmental contamination with multidrug-resistant organisms that persist despite routine manual cleaning. While hydrogen peroxide aerosolization and ultraviolet-C light devices have shown promise in reducing surface contamination, current evidence is inconsistent, mostly derived from single-center studies, and rarely linked to patient-centered outcomes.\n\nThe investigators will conduct this cluster-randomized, crossover trial in 12 Brazilian ICUs. Each ICU will sequentially implement three strategies: (1) usual surface disinfection; (2) usual surface disinfection followed by hydrogen peroxide aerosolization at 7.9% concentration, applied through a dedicated device inside a protective tent during terminal cleaning of patient beds; and (3) usual surface disinfection followed by automated ultraviolet-C irradiation, also applied under the same tent to shield adjacent occupied beds.\n\nThe primary outcome will be the antimicrobial utilization, measured as daily defined doses (DDD) of antimicrobials at the ICU level per 100 patient-days, with secondary outcomes including HAI incidence rate, environmental contamination with multidrug-resistant organisms, specific HAIs incidence rate (associated-ventilator pneumonia, central-line associated bloodstream infection, and catheter-associated urinary tract infection), and ICU length of stay costs.",[149,150,151,152,153],"Infection, Hospital","Antimicrobial","Pneumonia Associated With Mechanical Ventilation","Urinary Tract Infection(UTI)","Catheter Related Blood Stream Infections",[155,156,157,158,159,160,161,162],"Healthcare associated infections","Antimicrobial use","Intensive care units","pneumonia, ventilator-associated","Catheter-related infections","Urinary tract infections","Hydrogen Peroxide","Ultraviolet light","2026-04-10",{"date":165,"type":37},"2026-04-15",{"date":167,"type":37},"2026-01-05",{"date":169,"type":21},"2027-03-01",{"name":43,"class":44},12,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":182,"studyType":86,"phases":4,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100631600","long-term-assessment-of-patients-treated-in-the-icu-for-sepsis-100631600","NCT07502794","Long-term Assessment of Patients Treated in the ICU for Sepsis","A Prospective Clinical Registry Assessing In-Hospital Management and Post-Discharge Outcomes Among Patients Hospitalized for Sepsis","LAPTUS","Inclusion Criteria:\n\n* Clinical diagnosis of sepsis or septic shock during ICU hospitalization, according to the Sepsis-3 definition.\n* Age ≥18 years.\n* Written informed consent obtained from the participant or a legally authorized representative.\n\nExclusion Criteria:\n\n* Limited prognosis with a life expectancy of less than 3 months due to conditions not related to sepsis.\n* Refusal to participate in the study",{"count":181,"type":21},760,"12 Months","This study is a prospective, observational cohort clinical registry designed to describe clinical and epidemiological characteristics and outcomes of adult patients hospitalized with sepsis. Participants will be followed during hospitalization and after hospital discharge to evaluate short- and long-term outcomes.",[185],"Sepsis","2026-03-27",{"date":188,"type":37},"2026-03-31",{"date":190,"type":21},"2026-03",{"date":192,"type":21},"2027-12",{"name":43,"class":44},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100627364","ed-post-discharge-digital-follow-up-a-communication-comparison-100627364","NCT07447674","ED Post-Discharge Digital Follow-Up: A Communication Comparison","Comparison of Communication Strategies in Post-discharge Digital Reassessment of Patients Attended In-person in the Emergency Department. Back to Digital Study.","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Initial in-person evaluation at the Emergency Care Unit of Hospital Israelita Albert Einstein;\n* Emergency Severity Index (ESI) classification of 3, 4, or 5 during nursing triage;\n* In-person medical evaluation confirming low-risk classification;\n* Request for complementary laboratory tests;\n* Acceptance of digital reassessment after discharge;\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Request for blood culture testing;\n* Request for imaging studies (except chest X-ray evaluated in the Emergency Care Unit prior to discharge);\n* Laboratory tests with an expected turnaround time greater than 24 hours;\n* Change in clinical complexity level after medical evaluation;\n* Failure to transfer the discharged patient's identification to the Telemedicine Center;\n* Activation of a scheduled contingency plan at external units preventing timely patient registration in the telemedicine system as required by the program;\n* Lack of access to a smartphone with WhatsApp and email for communication.",{"count":202,"type":21},466,[24],"Emergency department overcrowding is a universal phenomenon associated with worse patient outcomes and a negative impact on healthcare teams. Telemedicine has been routinely implemented as a strategy to mitigate the harmful effects of overcrowding, particularly in pre-hospital assessments and triage processes. Since April 2024, the Emergency Care Units of Hospital Israelita Albert Einstein (HIAE) have offered low-risk patients-after nursing triage and in-person medical evaluation-the option of administrative discharge followed by digital reassessment via telemedicine. Currently, the initial communication strategy consists of an audio telephone call conducted by the telemedicine nursing team. In this study, we aim to test the hypothesis that the addition of alternative communication strategies may be associated with improved outcomes. This prospective, single-center, randomized, open-label pilot study will be conducted at a telemedicine center that serves five Emergency Care Units of HIAE. The study population will include patients aged 18 years or older who spontaneously seek care at an Emergency Care Unit, are classified as ESI 3, 4, or 5 during nursing triage, undergo in-person medical evaluation confirming low-risk status, and have complementary laboratory tests requested. Patients will be excluded if imaging exams are requested, if laboratory tests are expected to have a turnaround time exceeding 24 hours, or if they do not have access to a smartphone with WhatsApp and email for communication. After administrative discharge from the Emergency Department, patients will be randomized to one of two communication strategies: standard care, consisting of telephone contact by the telemedicine nursing team, or an incremental strategy, which includes instructions to check laboratory results via an application, reminder messages prompting patient-initiated contact through WhatsApp and email, and a telephone call in cases where no spontaneous contact occurs. The primary endpoint will be the time elapsed between medical discharge from the Emergency Care Unit and patient contact with HIAE.",[206],"Emergency Department Overcrowding",[208,209,210,211,212],"Communication Strategies","Post-Discharge Digital Reassessment","Emergency Care Unit","Telemedicine","Patient Follow-Up","2026-03-18",{"date":215,"type":37},"2026-03-23",{"date":217,"type":21},"2026-05-01",{"date":219,"type":21},"2027-07-31",{"name":43,"class":44},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":54,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":45},"100623560","gastric-content-in-fasting-volunteers-and-in-tirzepatide-users-an-observational-and-cross-sectional-study-100623560","NCT07398222","Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study","Ultrasonographic Evaluation of Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Individuals currently using tirzepatide.\n* Individuals fasting for at least 8 hours for solids and 2 hours for clear liquids without residue.\n\nExclusion Criteria:\n\n* Pregnant or postpartum individuals.\n* Technical limitation for gastric ultrasound assessment.\n* Presence of risk factors for gastroparesis.\n* Use of prokinetic medications such as bromopride, metoclopramide or domperidone.",{"count":229,"type":21},30,"Introduction\n\nObesity and type 2 diabetes mellitus constitute a global public health problem. Medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity are a modern therapeutic option for both diseases. Liraglutide, semaglutide, dulaglutide and tirzepatide are representatives of this drug class, whose mechanism of action results in delayed gastric emptying, reduced gastric motility and increased gastric volume.\n\nTirzepatide, however, presents a dual agonist action, combining GLP-1 agonism with glucose-dependent insulinotropic polypeptide (GIP) agonism.\n\nThe presence of gastric content during anaesthesia may lead to pulmonary aspiration and the development of chemical pneumonitis, a potentially devastating complication. However, when there is a risk factor for delayed gastric emptying, despite adequate fasting, the stomach may still present residual content, and bedside ultrasonography is an effective, non-invasive and rapid method to measure this content and stratify aspiration risk.\n\nOur hypothesis is that most individuals using tirzepatide present a full stomach even after fasting times recommended in the literature.",[232],"Full Stomach Status",[234,235,236],"gastric ultrasonography","tirzepatide","full stomach","2026-02-04",{"date":239,"type":37},"2026-02-09",{"date":241,"type":37},"2026-01-26",{"date":243,"type":21},"2026-03-20",{"name":43,"class":44},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":263,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":271,"leadSponsor":273,"locationsCount":45},"100568824","evaluation-of-the-efficacy-of-diagnostic-support-algorithms-in-chest-x-rays--luana-trial-100568824","NCT06686251","Evaluation of the Efficacy of Diagnostic Support Algorithms in Chest X-rays- LuAna Trial","Evaluation of the Efficacy of Diagnostic Support Algorithms in Chest X-rays - LungAnalysis (LuAna): LuAna Stepped Wedge Trial","Inclusion Criteria:\n\n* Non-reported chest X-rays (XRts) of individuals aged over 18 years.\n* Individuals images with respiratory complaints.\n* Chest X-rays taken during the presence of these respiratory symptoms or while being followed up for respiratory disease.\n* Chest X-rays taken on any X-ray machine.\n* Chest X-rays that include at least one frontal view of the chest.\n\nExclusion Criteria:\n\n* Those whose chest X-ray was performed due to a history of trauma, pre-operative risk assessment, lung cancer screening, or exclusively for verifying the correct positioning of a peripheral intravenous catheter (PICC).\n* Chest X-rays with technical quality below the minimum required for proper interpretation and diagnosis.\n* Cases without at least one frontal view.\n* X-rays printed on regular paper.",{"count":253,"type":21},1470,[24],"This study aims to evaluate whether the use of AI as a physician support tool is associated with an increase in the detection rate of chest radiographic findings in adults with respiratory complaints, compared to diagnosis performed exclusively by doctors, without AI support. This is a cluster-randomized clinical trial, following the stepped wedge design, and adhering to the guidelines of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT). In this study, the Diagnostic Support Solution for Chest X-rays - LungAnalysis (LuAna), developed by the Hospital Israelita Albert Einstein (HIAE) within the PROADI-SUS Banco de Imagens, was used.\n\nThe clinical trial will be conducted in multiple centers with a diverse population from the public health system, to ensure that the algorithms are validated across a broad demographic profile. The expected benefits are significant, providing greater security for patients, increasing doctors' confidence in interpreting chest X-rays, promoting efficiency and cost savings for healthcare services, and offering promising prospects for other AI applications in imaging diagnostics.",[257,258,259,260,261,262],"Consolidation","Lung Injury","Pleural Effusion","Pneumothorax","Cardiomegaly","Edema Lung",[264,265,266],"Artificial Intelligence","Chest X-ray","Stepped wedge trial","2026-01-29",{"date":269,"type":37},"2026-02-02",{"date":167,"type":37},{"date":272,"type":21},"2026-12-01",{"name":43,"class":44},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":297,"leadSponsor":299,"locationsCount":4},"100619161","phase-1-stem-cell-mobilization-with-high-dose-plerixafor-in-patients-with-sickle-cell-disease-100619161","NCT07341022","STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE","HEMATOPOIETIC STEM CELL MOBILIZATION USING HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE: A CONTROLLED PHASE I\u002FII TRIAL.","MobiSCD","Inclusion Criteria:\n\nPatients with sickle cell disease 18 to 25 years old At least one allogeneic HSCT indication followin the Brazilian Bone Marrow Transplant Society (SIMÕES et al., \\[s.d.\\]) ECOG\u002F Karnofsky\u002FLansky scores \\> 80 Hemoglobin \\> 7 g\u002FdL, WBC counts \\> 3000\u002Fmm3, neutrophil counts \\> 1500\u002Fmm3, platelet counts \\> 150000\u002Fmm3 No evidence of severe hepatic disfunction, defined as aspartate aminotransferase and alanine aminotransferase \\\u003C 5 times ULN or bilirubin \\\u003C 2,5 times ULN No evidence of renal disfunction, defined as creatinine \\\u003C1,5 mg\u002FdL ou GFR\\> 60 mL\u002Fmin LVEF \\> 40% and no signals of pulmonary hypertension Negative serologies for HIV, HBV, HCV, syphilis, Chagas disease or HTLV Being able to undergo partial exchange transfusion to lower HbS \\\u003C30% within one week before CD34+ mobilization and collection No pregnancy or breastfeeding; acceptance to use two contraceptive methods during the study.\n\nExclusion Criteria:\n\nEmergency room admission or hospitalization in the past 14 days prior to first dose of study drug Major surgery in the past 30 days prior to first dose of study drug Active and painful splenomegaly or splenomegaly (size greater than upper limit of normal on examination).\n\nParticipant who, by medical history, requires rare donor registry RBC units for transfusion, or is unable to receive routine transfusion. Eligible study participants must have undergone prior work-up for the presence of red cell alloantibodies and confirmation of available compatible blood product support Known allergy to or contraindication for motixafortide administration, or medications routinely administered during apheresis Participant who has had a prior autologous or allogeneic transplantation, inclusive of gene therapy Active viral, bacterial, fungal, or parasitic infection. History of cancer, excluding squamous carcinoma of the skin and cervical carcinoma in situ.\n\nParticipant who has received experimental therapy within 4 weeks prior to providing informed consent Poorly controlled diabetes mellitus, as assessed by the Investigator Concomitant treatment with alternative investigational agent unable to be held for 30 days Unwillingness to use a highly effective method of contraception for 1 month after motixafortide Pregnancy Inability or unwillingness of research participant or legal guardian\u002F representative to give written informed consent.\n\nInability or unwillingness of research participant to hold hydroxyurea for 30 days prior to first dose of study drug","25 Years",{"count":171,"type":21},[285,286],"PHASE1","PHASE2","The objective of this study is to demonstrate whether high-dose plerixafor can effectively mobilize hematopoietic stem cells in patients with sickle cell disease. It will also learn about the safety of this drug in higher doses in these patients. The main questions it aims to answer are:\n\nDoes high-dose plerixafor mobilize enough hematopoietic stem cells? What medical problems do participants have when taking high-dose plerixafor?\n\nParticipants will:\n\nUndergo transfusion Take high-dose plerixafor Be submitted to stem cell collection by apheresis Visit the clinic 10 days after the procedure Be contacted by the research team 30 days after the procedure.",[289],"Sickle Cell Disease",[291,292,293],"sickle cell disease","plerixafor","stem cell mobilization",{"date":295,"type":37},"2026-01-14",{"date":68,"type":21},{"date":298,"type":21},"2028-06",{"name":43,"class":44},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":54,"sex":55,"minAge":308,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":327,"locationsCount":328},"100555546","active-health-education-to-increase-hpv-vaccine-coverage-in-youth-a-stepped-wedge-cluster-and-randomized-trial-100555546","NCT06513494","Active Health Education to Increase HPV Vaccine Coverage in Youth: A Stepped-wedge, Cluster, and Randomized Trial","A Stepped-wedge, Cluster, and Randomized Trial to Evaluate Active Health Education Methods to Increase Human Papillomavirus Vaccine Coverage in Youth","EDUCAVAC","Criteria for students\n\nInclusion Criteria:\n\n* Students of both sexes aged 9 to 14 years old.\n\nExclusion Criteria:\n\n* Students with a complete HPV vaccination (two doses) received.\n\nCriteria for Clusters\n\nInclusion Criteria:\n\n* The school has enrolled students aged 9 to 14 years old.\n\nExclusion Criteria:\n\n* Schools that do not have students aged between 9 and 14;\n* Schools that provided only distance education","9 Years","14 Years",{"count":145,"type":21},[24],"This study aims to evaluate the impact of active health education methodologies on increasing adherence to the HPV vaccine among schoolchildren. The project will involve 196 schools across Brazil, encompassing a total of 5,000 students.\n\nA stepped-wedge implementation design will be applied, with clusters being randomized every two months to one of four interventions.\n\nEach intervention will be implemented in 48 schools.",[314,315],"Vaccine Refusal","Vaccine Hesitancy",[317,318,319,320],"vaccination coverage","HPV vaccine","stepped-wedge design","students","2025-11-14",{"date":323,"type":37},"2025-11-18",{"date":325,"type":37},"2025-03-24",{"date":272,"type":21},{"name":43,"class":44},79,{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":55,"minAge":4,"maxAge":17,"enrollmentInfo":336,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":338,"conditions":339,"keywords":345,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":4},"100601619","prospective-clinical-registry-for-evaluation-of-exanthematous-infections-and-coinfections-100601619","NCT07112846","Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections","CRIUS","Inclusion Criteria:\n\nIndividuals from newborns (zero years old) to 18 years of age, of both sexes.\n\nSuspected individuals with the following criteria:\n\nMeasles: Presenting fever and rash associated with cough and\u002For runny nose and\u002For conjunctivitis, regardless of age or vaccination status;\n\nRubella: Presenting fever, rash, and lymphadenopathy, regardless of age or vaccination status;\n\nDengue and Chikungunya: Presenting myalgia, arthralgia, headache, retro-orbital pain, nausea, vomiting, rash, petechiae, positive tourniquet test, or leukopenia and\u002For lymph node enlargement;\n\nIndividuals who, meeting the above criteria, underwent sample collection for viral panel testing for the differential diagnosis of exanthematous diseases.\"\n\nExclusion Criteria:\n\n\\-",{"count":337,"type":21},830,"Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an extremely concerning scenario from both epidemiological and healthcare perspectives. In addition to this, the reemergence of childhood exanthematous diseases in several countries, including Brazil, is alarming and occurs due to declining vaccination coverage and increased migratory movements. These diseases present overlapping clinical symptoms, and their differential diagnosis is often challenging, which, in a context of dengue and Chikungunya epidemics like the current one, may lead to underreporting of diseases such as measles and rubella. This project aims to build a prospective registry of the occurrence of dengue, Chikungunya, measles, and rubella in various healthcare centers in Brazil, in order to better understand the epidemiological scenario, identify clinical variables associated with different diagnoses, and describe healthcare bottlenecks that may hinder proper reporting and identification of these diseases.",[340,341,342,343,344],"Exanthema","Dengue Fever","Chikungunya","Measles","Rubella",[346,347,342,348,349,350],"exanthema","dengue fever","measles","rubella","epidemiology","2025-08-01",{"date":353,"type":37},"2025-08-08",{"date":355,"type":21},"2025-09-01",{"date":357,"type":21},"2026-06-30",{"name":43,"class":44},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":22,"phases":368,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":45},"100600773","phase-2-a-phase-ii-randomized-trial-to-assess-maintenance-therapy-with-cemiplimab-versus-best-supportive-care-after-1st-line-platinum-based-chemotherapy-in-advancedrecurrent-vulvar-cancer-100600773","NCT07101848","A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED\u002FRECURRENT VULVAR CANCER","BRAVA VULVAR","Inclusion Criteria:\n\n1\\) Female participants. 2) At least 18 years old on the day of signing the informed consent. 3) Histologically confirmed diagnosis of vulvar squamous cell carcinoma, clinical stages III-IVA or recurrent disease not amenable to curative-intent therapy, or metastatic disease (stage IVB) - according to FIGO 2018 (International Federation of Gynecology and Obstetrics).4) Measurable disease (as per RECIST v1.1) prior to starting first-line chemotherapy. Lesions located in a previously irradiated area are deemed as measurable if progression has been shown in such lesions. 5) Previous chemotherapy performed in localized disease setting, with curative intent and platinum-based is allowed, provided that the time off this treatment is longer than 6 months. 6) Previous first-line chemotherapy should have been comprised of at least 4 cycles and no more than 6 platinum-based chemotherapy cycles. 7) No evidence of progressive disease after completing first-line chemotherapy (e.g., ongoing complete response (CR), (partial response) PR or stable disease (SD) as per RECIST v1.1 guidelines). 8) An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or 2.\n\nExclusion Criteria:\n\n* 1\\) History of allergy or hypersensitivity to the study drug components. 2) Persisting NCI CTCAE v5.0 Grade \\> 1 toxicity related to previous therapy; however, Grade ≤ 2 sensory neuropathy and Grade ≤ 2 chronic kidney disease are acceptable. 3) Previous immune therapy with IL-2, IFN-α, or anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-T cytotoxic lymphocyte related to antigen-4 (CTLA-4), or any other antibody or drug specifically targeted to T-cell co-stimulation or immune checkpoint pathways. 4) Untreated or active primary brain tumor, metastases to central nervous system, leptomeningeal disease or spinal cord compression. 5) History of allogenic organ transplant. 6) Ongoing or recent evidence (within 5 years) of significant autoimmune disease requiring treatment with systemic immunosuppressants. 7) History of other primary malignancy within the last 3 years, except locally curable cancers which have been apparently cured, such as skin basal- or squamous-cell cancer, superficial bladder cancer, breast carcinoma in situ or cervical carcinoma in situ. 8) Uncontrolled infection by human immunodeficiency virus, hepatitis B or C infection; or immunodeficiency diagnosis. 9) Have received a live vaccine within 4 weeks of the planned start of the study drug. 10) Have received any previous systemic biological therapy within 5 half-lives of the first study therapy dose.\n\nException: participants previously treated with bevacizumab, cetuximab, rituximab or other non-immunomodulating antibodies with half-lives longer than 7 days are allowed after a discussion with the sponsor, if at least 28 days have elapsed since last treatment. 11) Pregnant or breastfeeding women.",{"count":367,"type":21},42,[286],"This is a phase II, randomized study that will include 42 participants who have received 4 to 6 cycles of first-line platinum-based chemotherapy for advanced vulvar squamous cell carcinoma (SCC) not amenable to curative surgical treatment (FIGO 2018 stages III-IV - International Federation of Gynecology and Obstetrics) \u002F\n\nrecurrent disease, and who have not progressed at the end of these 4 to 6 cycles. Participants eligible for the study will be randomized between 4 and 8 weeks after the last chemotherapy cycle to receive: - Cemiplimab maintenance plus best supportive care: cemiplimab 350 mg IV every 3 weeks until week 24, disease progression, unacceptable toxicity or consent withdrawal. Patients who continue to derive clinical benefit on the experimental arm may continue to receive treatment until week 48. - Best supportive care.",[371],"Vulvar Cancers","2025-07-28",{"date":374,"type":37},"2025-08-03",{"date":376,"type":21},"2025-11-01",{"date":378,"type":21},"2028-12",{"name":43,"class":44},{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":387,"minAge":17,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":45},"100600771","phase-2-a-phase-ii-randomized-study-to-assess-maintenance-therapy-with-cemiplimab-versus-best-supportive-care-after-1st-line-platinum-based-chemotherapy-in-advancedrecurrent-penile-cancer-100600771","NCT07101822","A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED\u002FRECURRENT PENILE CANCER","BRAVA PENILE","Inclusion Criteria:\n\n1\\) Male participants. 2) At least 18 years old on the day of signing the informed consent. 3) Histologically confirmed diagnosis of penile squamous cell carcinoma, clinical stages III-IV or relapsed disease, not amenable of curative intent therapy - as per AJCC 8th edition. 4) Measurable disease (as per RECIST v1.1) prior to starting first-line chemotherapy. Lesions located in a previously irradiated area are deemed as measurable if progression has been shown in such lesions. 5) Previous chemotherapy performed in localized disease setting, with curative intent and platinum-based is allowed, provided that the time off this treatment is longer than 6 months. 6) Previous first-line chemotherapy should have been comprised of at least 4 cycles and no more than 6 platinum-based chemotherapy cycles. 7) No evidence of progressive disease after completing first-line chemotherapy (e.g., ongoing complete response (CR), (partial response) PR or stable disease (SD) as per RECIST v1.1 guidelines). 8) An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or 2.\n\nExclusion Criteria:\n\n1\\) History of allergy or hypersensitivity to the study drug components. 2) Persisting NCI CTCAE v5.0 Grade \\> 1 toxicity related to previous therapy; however, Grade ≤ 2 sensory neuropathy and Grade ≤ 2 chronic kidney disease are acceptable. 3) Previous immune therapy with IL-2, IFN-α, or anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-T cytotoxic lymphocyte related to antigen-4 (CTLA-4), or any other antibody or drug specifically targeted to T-cell co-stimulation or immune checkpoint pathways. 4) Untreated or active primary brain tumor, metastases to central nervous system, leptomeningeal disease or spinal cord compression. 5) History of allogenic organ transplant. 6) Ongoing or recent evidence (within 5 years) of significant autoimmune disease requiring treatment with systemic immunosuppressants. 7) History of other primary malignancy within the last 3 years, except locally curable cancers which have been apparently cured, such as skin basal- or squamous-cell cancer, superficial bladder cancer, breast carcinoma in situ or cervical carcinoma in situ. 8) Uncontrolled infection by human immunodeficiency virus, hepatitis B or C infection; or immunodeficiency diagnosis. 9) Have received a live vaccine within 4 weeks of the planned start of the study drug. 10) Have received any previous systemic biological therapy within 5 half-lives of the first study therapy dose. Exception: participants previously treated with bevacizumab,\n\ncetuximab, rituximab or other non-immunomodulating antibodies with half-lives longer than 7 days are allowed after a discussion with the sponsor, if at least 28 days have elapsed since last treatment","MALE",{"count":367,"type":21},[286],"This is a phase II, randomized study which will enroll participants given 4 to 6 cycles of first-line platinum-based chemotherapy treatment for advanced penile SCC not amenable by curative surgical treatment (stages III-IV as per American Joint Committeeon Cancer - AJCC - 8th) recurrent and who did not progress at the end of these 4 to 6 cycles. Participants eligible for the study will be randomized between 4 and 8 weeks after the last chemotherapy cycle to receive: - Cemiplimab maintenance plus best supportive care: cemiplimab 350 mg IV every 3 weeks until week 24, disease progression, unacceptable toxicity or consent withdrawal. patients who continue to derive clinical benefit on the experimental arm may continue to receive treatment until week 48. - Best supportive care.",[392],"Penile Cancer",{"date":374,"type":37},{"date":395,"type":21},"2025-12",{"date":378,"type":21},{"name":43,"class":44},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":413,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":422,"locationsCount":45},"100597033","e-natureza-blue-care-nature-based-virtual-reality-and-pain-perception-100597033","NCT07053228","e-Natureza Blue Care: Nature-based Virtual Reality and Pain Perception","e-Natureza Blue Care - Impact of Virtual Reality on Pain Perception, Mood States, and Analgesic Use in Patients With Cancer Pain: Randomized Clinical Trial.","e-NatBlue","Inclusion Criteria:\n\n* hospitalized oncological patients with chronic pain.\n* both sexes\n* aged 18 years or older\n* preserved clinical condition and communication abilities that allow participation in the study\n* report pain documented in the electronic medical record\n\nExclusion Criteria:\n\n* Patients who are unable to tolerate wearing the virtual reality (VR) headset for at least 8 minutes\n* blind patients\n* patients who experience any side effects or worsening clinical condition during the interview\u002Fintervention period\n* patients undergoing other complementary treatments",{"count":407,"type":21},130,[24],"This randomized clinical trial aims to evaluate the effectiveness of immersive nature-based virtual reality in managing chronic pain among oncology patients. The study seeks to expand non-pharmacological treatment options and contribute to the therapeutic arsenal available for chronic pain management in cancer care.The intervention utilizes immersive videos of diverse Brazilian natural environments to promote analgesic and emotional relief.",[411,412],"Cancer Pain","Palliative Care",[411,414,415],"Palliative care","Virtual reality","2025-07-01",{"date":418,"type":37},"2025-07-08",{"date":420,"type":21},"2025-08-15",{"date":103,"type":21},{"name":43,"class":44},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":55,"minAge":430,"maxAge":431,"enrollmentInfo":432,"targetDuration":433,"studyType":86,"phases":4,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":45},"100582206","immunoregulation-in-atherosclerosis-a-single-cell-rna-sequencing-study-100582206","NCT06860295","\"Immunoregulation in Atherosclerosis: A Single-Cell RNA Sequencing Study\"","The Architectural Immunoregulation in Atherosclerotic Disease: A Single-Cell RNA Sequencing and Spatial Biology Approach","Inclusion Criteria:\n\n* Patients diagnosed with ischemic cardiomyopathy due to advanced atherosclerosis, undergoing heart transplantation;\n* Patients with coronary artery disease submitted to coronary artery bypass graft surgery (CABG).\"\n* Aged between 40 and 75 years;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Patients with systemic inflammatory or autoimmune diseases;\n* History of cancer within the last 5 years or active malignancy;\n* Recent use (within the last 6 months) of immunosuppressive therapy.","45 Years","75 Years",{"count":229,"type":21},"2 Years","Atherosclerosis is the leading cause of acute cardiovascular events, such as myocardial infarction and stroke, and is a significant risk factor for cardiovascular mortality. The detailed understanding of the immune mechanisms and cellular transformations involved in the pathogenesis of atherosclerosis is still limited, and the use of single-cell RNA sequencing (scRNAseq) has revealed new cellular functions and subpopulations associated with disease progression. This study aims to identify cellular subpopulations, molecular pathways, and changes in gene expression related to the development of atherosclerosis in human coronary arteries. Using scRNAseq, the study seeks to characterize the transcriptomic landscape of cells present in atherosclerotic plaques and identify molecular signatures that reveal individual predispositions to specific phenotypes, such as disease susceptibility and response to therapies. The research will be conducted at the Albert Einstein Israeli Hospital in São Paulo and will involve samples from coronary arteries and atherosclerotic plaques of the explanted hearts of patients who have undergone heart transplants as well as from discarded material of coronary artery bypass graft surgery (CABG). With an estimated sample size of 20-30 plaques, the data obtained will allow for a detailed analysis of the molecular mechanisms involved in atherosclerosis, contributing to the development of specific therapeutic targets.",[436],"Atherosclerosis of Coronary Artery",[438,439,440],"Atherosclerosis","Single Cell RNA-sequencing","Immunology","2025-06-09",{"date":443,"type":37},"2025-06-10",{"date":445,"type":21},"2025-06-25",{"date":447,"type":21},"2027-04-25",{"name":43,"class":44},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":45},"100571750","prospective-and-multicentric-cohort-study-of-severe-and-very-severe-chronic-obstructive-pulmonary-disease-copd-in-brazil-scope-100571750","NCT06724315","Prospective and Multicentric Cohort Study of Severe and Very Severe Chronic Obstructive Pulmonary Disease (COPD) in Brazil (SCOPe).","SCOPe","Inclusion Criteria:\n\nSevere, very severe and symptomaitc COPD, according to GOLD definition: exposure, FEV1\u002FFVC ratio \\\u003C0,7:\n\n* GOLD B (mMRC\\>=2, CAT\\>=10), OR\n* GOLD E (\\>=2 moderate exacerbations or 1 severe), OR\n* GOLD 3 and 4 (FEV1 \\\u003C50%).\n\nExclusion Criteria:\n\nSevere interstitial lung disease (extent \\>50% on HRCT), OR Severe pulmonary hypertension (on triple therapy), OR Active cancer - undergoing systemic therapy.",{"count":457,"type":21},693,"Chronic obstructive pulmonary disease (COPD) is prevalent (8-20%) and is one of the leading causes of mortality. In 2019 according to WHO it was the third highest cause of death worldwide. In 2019 in Brazil respiratory diseases (Chapter J in the ICD10) were the third cause of death (176.073) with COPD (J44) accounting for 45.163 deaths (25,6% of respiratory and 3% overall). There is an upward trend for COPD mortality worldwide.\n\nThe disease also has a high morbidity leading to impairment in daily activity and quality of life.\n\nPatients with severe and very severe disease are at a higher risk for negative outcomes, including exacerbation (up to 2-3 per patient per year). This in turn increases the risk of future exacerbations and mortality, with heightened risk lasting up to two years after each event. It is impertive to evaluate which sub-groups are at an even higher risk and could be potential targets for intervention.\n\n\"The PLATINO study\" was conducted on 2004 and evaluated the prevalence of COPD in 5 cities, only one in Brazil - Sao Paulo. As the data is 20 years old it might not reflect the current epidemiological status and might not be representative of Brazil as a whole.\n\nUnderstanding this population, their clinical and laboratorial characteristics can help identify sub-groups with higher risk and potential for intervention. The current prevalence, causing agent and characteristics are not known in Brazil as well as detailed outcome data.",[460],"COPD (Chronic Obstructive Pulmonary Disease)",[462],"COPD; Exacerbation; Cardiovascular; Hospitalizations; Death;","2025-06-02",{"date":465,"type":37},"2025-06-05",{"date":467,"type":37},"2025-01-31",{"date":469,"type":21},"2026-12-15",{"name":43,"class":44},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":54,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":486,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":45},"100590299","feasibility-study-to-actively-disseminate-the-latin-america-and-the-caribbean-code-against-cancer-in-primary-healthcare-centers-100590299","NCT06965608","Feasibility Study to Actively Disseminate the Latin America and the Caribbean Code Against Cancer in Primary Healthcare Centers","Feasibility Study to Actively Disseminate the Latin America and the Caribbean Code Against Cancer in Primary Healthcare Centers in Aparecida de Goiania (Brazil) - FLACC-Brazil","FLACC-Brazil","Inclusion Criteria:\n\n* Adults (≥18 years old)\n* Registered at a participating primary healthcare center (UBS) in Aparecida de Goiânia\n* Healthcare professionals with at least three months of employment at a participating UBS\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n\\- Prior diagnosis of any cancer or currently undergoing cancer treatment",{"count":480,"type":21},1200,[24],"Phase II non-randomized four-arm study (before\u002Fafter pragmatic trial) that will test 2 different implementation strategies either combined or separately for the dissemination of the Latin America and the Caribbean Code Against Cancer within four different primary healthcare units in Aparecida de Goiânia.",[484,485],"Cancer","Latin America and the Caribbean Code Against Cancer (LAC Code)",[487,488,489,490,485],"Health Literacy","Cancer Prevention","Health Services Research","Implementation Science","2025-05-02",{"date":493,"type":37},"2025-05-11",{"date":495,"type":21},"2025-05",{"date":497,"type":21},"2025-11",{"name":43,"class":44},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":508,"conditions":509,"keywords":514,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":45},"100383528","impact-of-muscle-degeneration-in-chronic-low-back-pain-100383528","NCT04273828","Impact of Muscle Degeneration in Chronic Low Back Pain","Impact of Muscle Degeneration in Chronic Ow Back Pain in Patients Undergoing Neural Decompression","Inclusion Criteria:\n\n1. adults 18 years of age and older;\n2. with symptoms of lumbosacral neural compression (radiculopathy or neurogenic lameness);\n3. failed conservative treatment for at least 6 weeks;\n4. undergoing surgery for neural decompression (discectomy and \u002F or foraminotomy and \u002F or hemilaminectomy);\n5. with complete pre and postoperative medical records in all evaluations.\n\nExclusion Criteria:\n\n1. need for lumbar arthrodesis;\n2. deep infection requiring surgical cleaning;\n3. patients submitted to joint facet rhizotomy;\n4. active rheumatologic disease, including seronegative arthropathies.",{"count":507,"type":21},168,"Surgical interventions for the removal of intervertebral disc fragments or to enlarge a narrow spine canal are commonly performed worldwide and are considered efficient. Concomitant low back pain is not uncommon among patients with lumbar nerve compression and neurological symptoms. When present, controversy persists in the literature regarding its ideal management. Although neurological symptoms improve after decompressive surgery, the presence of residual chronic low back pain may worsen satisfaction scores and cause functional disability.\n\nThe hypothesis of the present study is that the presence of atrophy of the paraspinal and trunk muscles predicts chronic low back pain after lumbar neural decompression. If confirmed, this finding will aid in better planning of physical rehabilitation strategies for this group of patients, as well as a clearer prediction regarding surgical treatment outcomes for patients and health professionals.",[510,511,512,513],"Lumbar Spinal Stenosis","Lumbar Disc Herniation","Radiculopathy","Back Pain",[515,516,517,518],"back pain","lumbar disc herniation","lumbar spinal stenosis","Decompression, surgical","2025-03-10",{"date":521,"type":37},"2025-03-13",{"date":523,"type":37},"2020-04-06",{"date":525,"type":21},"2025-06-27",{"name":43,"class":44},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":54,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":537,"briefSummary":538,"conditions":539,"keywords":543,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":45},"100573388","a-multifaceted-intervention-on-reducing-immunization-errors-100573388","NCT06745635","A Multifaceted Intervention on Reducing Immunization Errors","A Multifaceted Intervention on Reducing Immunization Errors: a Pragmatic, Stepped-wedge, Cluster Randomized Trial","THEIA","Cluster Inclusion Criteria\n\n* Health units with vaccination rooms administering at least 2,000 doses of vaccines\u002Fimmunobiologicals per month,\n\nCluster Exclusion Criteria\n\n* Primary health units that do not provide consistent vaccination services to the population.",{"count":536,"type":21},72,[24],"The goal of this trial is to reduce the general error related to vaccines and immunizations (composited on secondary endpoint), after 11 moths of folow-up after cluster randomization and stepped wedge on primary care on brazilian public health.\n\nThe main questions it aims to answer are:\n\n1. To evaluate the effectiveness of a multifaceted intervention in vaccination rooms in reducing vaccination errors.\n2. To describe the rate of adverse events following immunization (AEFI) and the associated factors.",[540,541,542],"Vaccines","Vaccines Adverse Reaction","Vaccine Practice",[544,545,546,547,548,549,550,551,552,553],"Cluster-randomized controlled trial","Multifaceted intervention","Quality improvement in immunization","Vaccination errors","Vaccination safety","Primary health care","Vaccination room management","Cold chain management","Public health improvement","Health systems implementation","2025-02-07",{"date":556,"type":37},"2025-02-11",{"date":558,"type":21},"2025-07-03",{"date":560,"type":21},"2026-12-30",{"name":43,"class":44},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":431,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":45},"100516972","phase-1-expansion-of-virus-specific-lymphocytes-for-cell-therapy-100516972","NCT06011486","Expansion of Virus-Specific Lymphocytes for Cell Therapy","Expansion of Virus-Specific Lymphocytes for Cell Therapy in Immunosuppressed Patients Who Underwent Bone Marrow Transplantation.","Inclusion Criteria:\n\n* Be able to provide signed informed consent.\n* Must be between 18 and 75 years old at the time of signing the consent form\n* Having undergone allogeneic hematopoietic stem cell transplantation (related, unrelated, haploidentical or cord blood transplant)\n* Negative pregnancy test for women of childbearing age (non-fertile age defined as post-menopausal over one year, or surgically sterilized); Acceptance of the use of contraceptive methods by sexually active men and women of childbearing age;\n* Present with clinically significant CMV infection and one of the following conditions:\n* Refractory CMV infection, defined as over a 1log increase in blood or plasma CMV copies number after 2 weeks of treatment with appropriate anti-CMV medication (treatment with ganciclovir, valganciclovir, or foscarnet)\n* Probable refractory CMV infection, defined as persistence of CMV DNA in blood or plasma at the same level or under 1 log increase after 2 weeks of treatment with appropriate anti-CMV medication (treatment with ganciclovir, valganciclovir, or foscarnet)\n* Presence of resistant CMV, defined by the presence of a known genetic mutation that reduces susceptibility to one or more antiviral medications\n* Refractory CMV disease, defined as worsening of signs and symptoms and\u002For progression to CMV disease after 2 weeks of appropriate antiviral therapy\n* Restrictions or complications related to conventional therapy, which make it impossible to carry out conventional drug treatment defined as cytopenias with neutrophils under 1000 per microliter, platelets under 100,000 per microliter related to the use of ganciclovir or valganciclovir and nephrotoxicity with an increase of 1.5 times in the baseline creatinine with the use of foscavir.\n\nExclusion Criteria:\n\n* Patients who do not meet the inclusion criteria\n* Patients who do not agree to participate in the study or sign the consent form\n* Patients reporting allergy to murine antibodies or iron-dextran\n* Patients with grade 3 or 4 graft versus host disease\u002Fgraft versus host disease in activity\u002Ftreatment\n* Pregnant or lactating patients\n* Patients with uncontrolled bacterial and\u002For fungal infections",{"count":570,"type":21},10,[285],"Infections and reactivation of human cytomegalovirus (CMV), adenovirus, Epstein-barr and polyoma virus infections are frequent causes of morbidity and mortality and are a source of serious complications in patients undergoing allogeneic bone marrow transplantation.\n\nIn this project we will prepare specific T lymphocytes from blood donor, select cells CMV-specific by interferon gamma capture and treat patients with CMV viral infections. These cells will be used as antiviral therapy in transplanted patients whom do not respond to conventional therapies or in patients whose conventional therapy may be toxic in the context of transplantation. In this context, CMV reactivation can lead to serious complications in patients, such as irreversible neurological changes, pulmonary, gastrointestinal and ophthalmologic complications, among others, in addition to prolonged hospitalizations, leading to significant morbidity and mortality , both in the health sector public as private.\n\nThis project may represent an important therapeutic modality using cell of the shelf as a source of therapy for different patients and contributing to reduced morbidity \u002F mortality after transplantation, as well as a reduction in the hospitalization period.",[574,575],"CMV Viremia","CMV","2024-10-22",{"date":578,"type":37},"2024-10-24",{"date":580,"type":37},"2024-06-10",{"date":582,"type":21},"2026-06-10",{"name":43,"class":44},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":55,"minAge":591,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":22,"phases":595,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":4},"100538613","the-effects-of-ischemic-conditioning-in-individuals-with-parkinsons-disease-100538613","NCT06293118","The Effects of Ischemic Conditioning in Individuals with Parkinson's Disease","The Chronic Effect of Ischemic Conditioning on Motor Function, Cognitive Performance, and Immune System in Individuals with Parkinson's Disease","Inclusion Criteria:\n\n* PD patients aged 40 years or older;\n* Diagnosis of PD without cognitive complaints or with complaints, but without impact on daily activities;\n\nExclusion Criteria:\n\n* Patients with uncontrolled diabetes mellitus or peripheral neuropathy;\n* Uncontrolled arterial hypertension (BP\\>160\u002F100mmHg);\n* Uncontrolled diabetes (Fasting glucose \\> 250mg\u002Fdl, peripheral retinopathy or diabetic ketoacidosis);\n* Uncontrolled dyslipidemia (total chol \\> 220mg\u002FdL);\n* Pre-existing autoimmune diseases;\n* Infectious conditions for less than 1 month;\n* Neurological problems that prevent training from being carried out;\n* History of anemia, cerebral vascular disease, myocardial infarction in the last 6 months;\n* Previous deep vein thrombosis;\n* Smoking \\\u003C 6 months;\n* Symptomatic peripheral arterial obstructive disease;\n* Cognitive dysfunction: Moca \\\u003C 24.","40 Years","90 Years",{"count":594,"type":21},34,[24],"Ischemic conditioning (IC) is a promising therapy that can mimic the physiological effects of physical exercise. IC consists of using a cuff to measure blood pressure and calibrate 200 mmHg on the upper or lower limb. Thus, at alternating intervals of 5 minutes, ischemia or reperfusion occurs, depending on whether the cuff is inflated or deflated. IC induces changes in spinal cord excitability for the last reflex reactions of recruited motoneurons with improved balance control in healthy young people and improved learning in the elderly. The objective of the present study is to evaluate the chronic effect of IC on the motor function and cognitive performance of patients with Parkinson's disease. Furthermore, the investigators will evaluate secondary outcomes such as mobility, quality of life, and immunological responses.",[598],"Parkinson Disease",[600,601,602,603,604],"ischemic conditioning","immune system","motor function","cognitive performance","Parkinson disease","2024-10-16",{"date":607,"type":37},"2024-10-18",{"date":609,"type":21},"2025-03-01",{"date":611,"type":21},"2027-09-01",{"name":43,"class":44},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":623,"conditions":624,"keywords":626,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":637,"locationsCount":45},"100369842","computed-tomography-with-stress-maneuvers-for-evaluation-of-distal-tibiofibular-syndesmosis-instability-ctmets-100369842","NCT04095598","Computed Tomography with Stress Maneuvers for Evaluation of Distal Tibiofibular Syndesmosis Instability (CTMETS)","Comparative Computed Tomography with Stress Maneuvers for Evaluation of Distal Tibiofibular Syndesmosis Instability in Adults After Acute Ankle Sprain: a Test Accuracy Study","CTMETS","Inclusion criteria:\n\n* Adults older than 18 years;\n* One episode of an ankle sprain;\n* Sprain episode occurred up to 3 weeks prior;\n* Positive orthopedic evaluation for suspected syndesmotic injury.\n\nExclusion criteria\n\n* Bilateral ankle sprain;\n* Previous ankle surgery;\n* Ankle fractures and dislocations (except avulsion fractures in ligamentous insertions or fracture of the posterior malleolus related to syndesmotic injury);\n* Congenital or acquired ankle deformities;\n* Infection, inflammatory, or neuropathic ankle arthropathies.",{"count":622,"type":21},133,"The main aim of this study was to investigate which strategy can diagnose more accurately syndesmotic instability among an existing index test (ankle CT in neutral position) and two new add-on index tests (ankle CT in a stress position with extended-knees and ankle CT in a stress position with flexed-knees). This study hypothesized that the two add-on ankle CT with stress maneuvers (CTSM) have a more accurate capability of diagnosing syndesmotic instability than ankle CT in a neutral position (CTNP) alone. The secondary objective is to investigate the participants' disability outcomes by applying the Foot and Ankle Ability Measure questionnaire.",[625],"Ankle Sprain",[627,628,629,630],"High ankle sprain","Syndesmotic instability","Computed Tomography","Stress maneuver","2024-10-15",{"date":633,"type":37},"2024-10-17",{"date":635,"type":37},"2018-09-01",{"date":192,"type":21},{"name":43,"class":44},{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":4,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":645,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":647,"conditions":648,"keywords":650,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":654,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":658,"locationsCount":45},"100309161","prognostic-factors-in-zygapophyseal-osteoarthritis-infiltration-a-prospective-cohort-study-100309161","NCT03304730","Prognostic Factors in Zygapophyseal Osteoarthritis Infiltration: a Prospective Cohort Study","Prognostic Factors of Efficacy in Corticoid and Anesthetic Joint Infiltration for the Treatment of Patients with Low Back Pain Secondary to Zygapophyseal Osteoarthritis: a Prospective Cohort Study","Inclusion criteria\n\nThe following are inclusion criteria for participants:\n\n* Older than 18 years;\n* Fluent or native Portuguese language speaker;\n* Continuous or intermittent low back pain for at least three months;\n* Low back pain with or without irradiation to the gluteal region indicating facet syndrome (pain is aggravated by spine extension or bending toward the affected side; pain is exacerbated by prolonged sitting or walking up steps, as well as retaining one position for a prolonged time);\n* Failure of traditional treatment includes, but is not limited to, physical or drug therapy;\n* Understand the purpose of the study;\n* Voluntarily provide a free and informed consent form, by themselves or through their partners, and complete the questionnaires, before undergoing infiltration, over the telephone or online during the follow-up.\n\nExclusion criteria\n\nThe following are exclusion criteria for participants:\n\n* Younger than 18 years old,\n* Symptomatic lumbar spinal stenosis with claudication or radiculopathy;\n* Evidence of radiculopathy;\n* Active rheumatologic diseases;\n* Congenital or acquired deformities of the lumbar spine;\n* Fracture or sequel of lumbar spine fracture of traumatic, pathological or osteoporotic origin;\n* Surgical manipulation of the lumbar spine;\n* MRI scans of limited quality and incomplete sequences;\n* Treated with systemic steroids less than one month before the IFI;\n* Treated with IFI with steroids within the last six months;\n* Diagnosed with uncontrolled diabetes mellitus;\n* History of allergy to anesthetics or adverse reaction to steroids;\n* Pregnant women or women who breastfed;\n* Who could not be contacted over the phone during follow-up.",{"count":646,"type":21},147,"Magnet Resonance Image findings of facet osteoarthritis and patient characteristics are prognostic factors for improving or worsening the clinical outcome after treatment with facet infiltration.",[649],"Degenerative Arthropathy of Lumbar Spinal Facet Joint",[651,652,653],"Zygapophyseal Joint","Low Back Pain","Spine Osteoarthritis",{"date":633,"type":37},{"date":656,"type":37},"2017-09-01",{"date":192,"type":21},{"name":43,"class":44},{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":4,"eligibilityCriteria":665,"healthyVolunteers":12,"sex":55,"minAge":17,"maxAge":4,"enrollmentInfo":666,"targetDuration":668,"studyType":86,"phases":4,"briefSummary":669,"conditions":670,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":677,"leadSponsor":679,"locationsCount":107},"100499498","observational-prospective-cohort-study-of-mpox-infection-in-brazil-netpox-100499498","NCT05784038","Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)","Observational, Prospective, Cohort Study of Mpox Infection in Brazil - NETPOX Cohort","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years with confirmed MPOX infection.\n\n(laboratory-confirmed monkeypox infection is defined as determined by PCR, culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 4 days of randomization)\n\nExclusion Criteria:\n\n* Inability to provide informed consent;\n* Patient who, judging by the study team, does not have a condition for decentralized follow-up",{"count":667,"type":21},80,"10 Months","The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus in Brazil. The expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.",[671,672],"Monkeypox","MPOX","2024-07-16",{"date":675,"type":37},"2024-07-17",{"date":673,"type":37},{"date":678,"type":21},"2026-12",{"name":43,"class":44},""]